{"id":203835,"date":"2026-11-12T10:52:14","date_gmt":"2026-11-12T10:52:14","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/203835\/"},"modified":"2026-11-12T10:52:14","modified_gmt":"2026-11-12T10:52:14","slug":"eli-lilly-becomes-first-drugmaker-to-have-a-glp-1-weight-loss-pill-approved-in-china","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/203835\/","title":{"rendered":"Eli Lilly becomes first drugmaker to have a GLP-1 weight loss pill approved in China"},"content":{"rendered":"<p>Eli Lilly on Thursday became the first company to have a GLP-1 weight-loss pill approved in China, gaining a leg up on Danish rival Novo Nordisk in the world&#8217;s second-largest pharmaceutical market.<\/p>\n<p>So far, only GLP-1 weight-loss injections have been available in China.<\/p>\n<p>The pill, orforglipron, will compete for market share in China with Lilly&#8217;s own once-weekly GLP-1 weight-loss injection as well as with similar injections from Novo, Pfizer and local \u200ccompany Innovent Biologics.<\/p>\n<p>The GLP-1 class of drugs mimic a gut hormone to curb \u200bappetite and regulate blood sugar in patients with diabetes.<\/p>\n<p>Novo and Lilly believe weight-loss pills could \u200battract patients reluctant to use injections. Novo has also submitted an application to sell the oral version of Wegovy in China.<\/p>\n<p>Oral therapies account for about a third of US obesity prescriptions following the rollout of Novo&#8217;s Wegovy pill in January this year, according to Novo presentations in September.<\/p>\n<p>China&#8217;s \u200bNational Health Commission has said the proportion of overweight or obese people \u2060in the country could reach more than 65% by 2030, up from roughly 50% in 2020.<\/p>\n<p>Annual sales of GLP-1 therapies for weight management in China could reach 30 billion yuan ($4.5 billion) in the next five to seven years, up from an estimated 3 billion yuan to 4 billion yuan at present, Yang Huang, J.P. Morgan&#8217;s head of China healthcare research, has forecast.<\/p>\n<p>Lilly did not immediately respond to a request for comment on how it will price orforglipron in China or when it would be available.<\/p>\n<p>What appeared to be a promotion for the drug appeared on a mobile app from Chinese e-commerce company JD.com on Thursday. A spokesperson for JD.com did not immediately respond to a request for comment.<\/p>\n<p>Reuters<\/p>\n","protected":false},"excerpt":{"rendered":"Eli Lilly on Thursday became the first company to have a GLP-1 weight-loss pill approved in China, gaining&hellip;\n","protected":false},"author":2,"featured_media":203836,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[2574,174,33432,4007,33431,17428,33434,33433,33435,1736,272,33436,135,8313,33430,1827],"class_list":["post-203835","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-breaking-news","tag-china","tag-english-daily","tag-finance","tag-free-newspaper","tag-headlines","tag-hong-kong-media","tag-hong-kong-news","tag-hong-kong-news-media","tag-latest-news","tag-novo-nordisk","tag-sing-tao","tag-sports","tag-standard","tag-the-standard","tag-world"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117603096840463721","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/203835","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=203835"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/203835\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/203836"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=203835"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=203835"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=203835"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}